Brief: Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018
06/10/2025 13:09
Oct 6 (Reuters) - Alvotech SA ALVO.O: KASHIV BIOSCIENCES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA AND ACCEPTANCE OF MARKET AUTHORIZATION APPLICATION BY EUROPEAN MEDICINES AGENCY FOR ADL-018, A PROPOSED BIOSIMILAR TO XOLAIR® (OMALIZUMAB) Source text: ID:nBwblfJYra Further company coverage: ALVO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study